Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Aug 14;8(8):e70784.
doi: 10.1371/journal.pone.0070784. eCollection 2013.

Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis

Vincent C H Chung  1 , Polly H X Ma, David S C Hui, Wilson W S Tam, Jin Ling Tang
Affiliations
Meta-Analysis

Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis

Vincent C H Chung et al. PLoS One. .

Abstract

Background: Inhaled bronchodilators are the first-line therapy for COPD. Indacaterol is a novel addition to existing long-acting bronchodilators.

Objectives: Systematic review of randomized controlled trials (RCT) ON efficacy and safety of indacaterol as compared: 1) with placebo at different dosages, 2) with existing bronchodilators; (3) as add-on treatment to tiotropium.

Methods: We searched 13 electronic databases, including MEDLINE, EMBASE and CENTRAL, and contacted the manufacturer for unpublished data. Primary outcome was mean FEV1 change at 12(th) week, secondary outcomes included changes in SGRQ, TDI and BODE index at 6 months, exacerbation at 1 year, and worsening of symptoms.

Results: Twelve eligible RCTs of moderate risk of bias included data from 10,977 patients. Compared to placebo, indacaterol improved FEV1 by a weighted mean difference (WMD) of 0.16 L (95%CI: 0.15, 0.18 L, p<0.001), homogeneously above the minimally important difference of 0.10 L. It offered clinically relevant improvement in all secondary outcomes except exacerbation. Magnitude of benefit did not differ significantly by dosage, but one treatment related death was reported at 300 ug. Efficacy of Indacaterol was similar to formoterol and salmeterol (FEV1 WMD = 0.04 L, 95%CI: 0.01 L, 0.07 L, p = 0.02); and tiotropium (FEV1 WMD = 0.01 L, 95%CI: -0.01, 0.03 L, p = 0.61). The use of indacaterol on top of tiotropium yielded additional improvement on FEV1 (WMD = 0.07 L, 95%CI: 0.05 L, 0.10 L, p<0.001).

Conclusion: Indacaterol is safe and beneficial for patients with COPD at dosage ≤150 ug. It may serve as a good alternative to existing bronchodilators, or as an add-on to tiotropium for unresponsive patients. Use of higher dosage requires further justification.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. The flow of literature search.
Figure 2
Figure 2. Indacaterol versus Placebo on FEV1 at 12 weeks.
Figure 3
Figure 3. Indacaterol versus other long acting β2 agonist bronchodilators on FEV1 at 12 weeks.
Figure 4
Figure 4. Indacaterol versus Tiotropium on FEV1 at 12 weeks.
Figure 5
Figure 5. Indacaterol plus Tiotropium versus Tiotropium plus placebo on FEV1 at 12 weeks.
See this image and copyright information in PMC

References

    1. Mannino DM, Buist AS (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765–73. - PubMed
    1. Michaud CM, Murray CJ, Bloom BR (2001) Burden of disease–implications for future research. JAMA 285: 535–9. - PubMed
    1. Bustacchini S, Chiatti C, Furneri G, Lattanzio F, Mantovani LG (2011) The economic burden of chronic obstructive pulmonary disease in the elderly: results from a systematic review of the literature. Curr Opin Pulm Med 17(S1): S35–41. - PubMed
    1. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, et al. (2011) Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 155: 179–91. - PubMed
    1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 187: 347–65. - PubMed

MeSH terms